Antineoplastic activities of Gd@C₈₂(OH)₂₂ nanoparticles: tumor microenvironment regulation

Yiye Li1, Yanhuan Tian, Guangjun Nie

  • 1National Center for Nanoscience and Technology (NCNST), CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, Beijing 100190, China.

Insights

Gd@C(82)(OH)(22) nanoparticles show potent antitumor effects by modulating the tumor microenvironment. These novel hydroxylated metallofullerenes offer biocompatibility and diverse biological activities for cancer therapy.

Area of Science:

  • Nanomedicine
  • Oncology
  • Biochemistry

Background:

  • Tumor microenvironment plays a critical role in cancer initiation and progression.
  • Targeting the tumor microenvironment is a key strategy for developing effective cancer therapies.
  • Gd@C(82)(OH)(22) nanoparticles represent a novel class of endohedral hydroxylated metallofullerenes.

Purpose of the Study:

  • To summarize the physiochemical properties and antitumor activities of Gd@C(82)(OH)(22) nanoparticles.
  • To elucidate the mechanisms by which these nanoparticles regulate the tumor microenvironment.
  • To highlight their potential as a nanomedicine for cancer treatment.

Main Methods:

  • Review of existing literature on Gd@C(82)(OH)(22) nanoparticles.
  • Analysis of their nanoscale physiochemical properties.
  • Investigation of their biological effects on the tumor microenvironment.

Main Results:

  • Gd@C(82)(OH)(22) nanoparticles exhibit excellent biocompatibility and significant antineoplastic activity.
  • Their efficacy stems from diverse biological effects, not direct cytotoxicity.
  • Key mechanisms include antioxidation, immune activation, angiogenesis inhibition, cancer cell trapping, and overcoming drug resistance.

Conclusions:

  • Gd@C(82)(OH)(22) nanoparticles are a promising nanomedicine for cancer therapy.
  • Their ability to modulate the tumor microenvironment underlies their therapeutic potential.
  • Further research into their mechanisms can optimize their clinical application.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...